摘要
银屑病是一种常见的、易复发及难根治的慢性免疫性皮肤病,给患者生活带来极大困扰。对银屑病发病机制的深入认识将有助于新药物靶标发现和治疗药物的开发。近年来,"白细胞介素-23/T辅助细胞17(IL-23/Th17)细胞轴"在银屑病发病中的重要作用越来越受到关注,靶向该细胞轴的一些药物也已成功上市用于改善银屑病,获得良好的疗效。本综述围绕"IL-23/Th17细胞轴"系统阐述了参与银屑病发病过程中的多种免疫细胞如树突状细胞、巨噬细胞、中性粒细胞和T细胞的作用,总结了靶向该细胞轴治疗银屑病的多种治疗性抗体。此外,本综述还对目前治疗银屑病的小分子药物也进行了总结。
Psoriasis,bringing great trouble to patients’life,is a common chronic immune skin disease which is relapsed and difficult to cure.Further understanding of the pathogenesis of psoriasis will be benefit for potential drug targets and the development of therapeutic drugs.In recent years,"interleukin-23/T helper17(IL-23/Th17)cell axis"has attracted more and more attention in the pathogenesis of psoriasis.Some drugs targeting the cell axis have also been successfully listed in the market to improve psoriasis and achieved good results.This review focuses on the"IL-23/Th17 cell axis"system to elaborate the role of a variety of immune cells involved in the pathogenesis of psoriasis,such as dendritic cells,macrophages,neutrophils and T cells,and summarizes multiple therapeutic antibodies targeting this cell axis in the treatment of psoriasis.In addition,this review also summarizes the current small molecule drugs for the treatment of psoriasis.
作者
朱雨雨
宋承霖
孙洋
ZHU Yu-yu;SONG Cheng-lin;SUN Yang(State Key Laboratory of Pharmaceutical Biotechnology,Department of Biotechnology and Pharmaceutical Sciences,School of Life Sciences,Nanjing University,Nanjing 210023,China)
出处
《药学学报》
CAS
CSCD
北大核心
2020年第7期1393-1400,共8页
Acta Pharmaceutica Sinica
基金
国家自然科学基金资助项目(81872877)
2018年江苏省研究生科研创新计划项目(KYCX18-0041)。
